Treatment tolerance and compliance
DISEASE PROGRESSION, BEST
From September 2019 to March 2022, in a total of 36 enrolled pts (median age 63, 95%CI:48–74 years old), 34 pts completed CCRT. Three patients excluded due to violation of the exclusion criteria (1 pt) and consent withdrawal (2 pts). Finally, 33 pts were included in the final analysis, all of which had complete baseline data and safety evaluation (Trial profile.After CCRT, 90.9% (30/33) of patients entered the sintilimab maintenance stage, and 3 patients had disease progression (Best percentage change in the sum of diameters of target lesions from baseline 